Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 235Neoplasms 207Carcinoma, Non-Small-Cell Lung 101Colorectal Neoplasms 99Prostatic Neoplasms 93Lung Neoplasms 78Multiple Myeloma 53Melanoma 52Pancreatic Neoplasms 50Head and Neck Neoplasms 50Neoplasm Metastasis 48Leukemia, Myeloid, Acute 44Carcinoma, Hepatocellular 43Ovarian Neoplasms 39Brain Neoplasms 39Squamous Cell Carcinoma of Head and Neck 37Recurrence 37Glioblastoma 33Uterine Cervical Neoplasms 32Glioma 31Sarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Stomach Neoplasms 28Lymphoma, Non-Hodgkin 28Lymphoma 27Colonic Neoplasms 27Carcinoma, Renal Cell 26Lymphoma, Follicular 25Esophageal Neoplasms 24Rectal Neoplasms 23

Interventions

Letrozole 2palbociclib 1Fulvestrant 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Estrogen Receptor-positive Breast Cancer × 90 days × Clear all
NCT03962647 2026-04-30

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Completed
31 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡